The immune system comprises a compendium of specialized cells, tissues, and organs that protect the organisms from a myriad of pathogens and can survey and destroy cancer cells. The recognition of the cognate antigens by the T cell and B cell receptor (TCR and BCR), which is required for the activation of antigen-specific effector functions of T and B lymphocytes is executed in the context of the immunological synapse (IS). The IS is a specialized cell-cell interaction that acts as a signaling platform for the integration of signals leading to intercellular communication, in order to ensure efficient TCR and BCR-evoked signal transduction.
IS formation triggers the asymmetric reorganization of the actin and tubulin cytoskeleton and the convergence of secretory vesicles, including multivesicular bodies (MVBs) (, ) and other lysosome-related organelles (LROs), toward the microtubule-organizing center (MTOC), which polarizes along with the secretory vesicles to the IS (). These traffic events lead to the exocytosis of LROs and cytokine-containing vesicles at the synaptic cleft. LRO content secreted at the IS (including perforin, granzymes and intraluminal vesicles released as exosomes) plays an important role in cytotoxic T lymphocyte (CTL) mediated cytotoxicity (), activation-induced cell death (), germinal center reaction, antibody production, and antigen extraction at the B lymphocyte IS (), whereas cytokine secretion plays an important role in antigen-presenting cell (APC) stimulation ().
In the context of antigen recognition, MVB degranulation and extracellular vesicle (EV) secretion, we have received a relevant review on microvilli and EVs at the IS (Ruiz-Navarro et al.). This contribution addresses the different classes of EVs detected at the IS, emphasizing the most recent findings on microvilli/lamellipodium-produced EVs. Microvilli connections are F-actin-rich protrusions that act as sensors involved in the palpation of antigen-presenting cells and antigen sensing and are fundamental initiators of IS assembly (Figure 1); however, recent evidence has shown an important role of microvilli not only in antigen sensing but also in effector functions by producing EVs. The signals that lead to the polarized secretion of EVs at the synaptic cleft are discussed in this study, showing that the IS architecture fulfills a fundamental task in this secretion route.
Figure 1
While significant attention has been focused on the T, B lymphocyte, and NK cell side of the IS, particularly on its role as a secretory platform for polarized secretion of diverse secretory vesicles (), much less is known about the trafficking events occurring at the tumor cell side of the IS. Recent evidence supports the notion that tumor cells and APCs can rapidly reorganize their actin and tubulin cytoskeleton toward CTLs (), Th cells () and NK cells (). This reorganization underlies the polarized secretion of tumor cell LROs toward CTLs and NK cells, providing mechanisms that allow the tumor cell to evade the immune system (). These results indicate that a view of IS based exclusively on analyses from the effector cell side of the synaptic cleft may only provide a partial view of the complex structural and functional interrelationship between the effector and the tumor cell. Indeed, a more holistic approach, which should include the study of the events occurring on the tumor cell/APC side of the IS is needed to achieve a global picture of IS structure and function. In this context, we have received an interesting contribution (Biolato et al.) on the reorganization of the F-actin cytoskeleton in human breast adenocarcinoma cells and melanoma cells forming IS with human NK cells. The authors, using elegant super-resolution imaging approaches based on a pH-sensitive probe for CD63+ vesicle exocytosis, suggest that directed secretion may occur from tumor cells toward attacking NK cells. Their findings reveal that synaptic remodeling of the actin cytoskeleton within cancer cells interacting with NK cells is associated with increased recruitment and fusion of MVBs at the IS, as was shown previously on the T lymphocyte side of the IS (, ) (Ruiz-Navarro et al.). This suggests that cancer cell-derived exosomes may be released into the IS, raising important questions about the properties of these exosomes and their potential role in conferring resistance to NK cell-mediated cytotoxicity. Although further investigation is needed to formally demonstrate IS-triggered exosome secretion by the tumor cells, and to reveal both the mechanism involved and the consequences of MVB secretory traffic, this contribution highlights a potentially overlooked mechanism by which cancer cells may evade immune destruction.
Regarding the translational implications that may be derived from applying such a holistic approach to IS studies, T-cell redirecting approaches to selectively eliminate tumor cells are useful strategies for cancer immunotherapy and are based on the formation of T cell-target cell conjugates (), although these approaches have poor therapeutic results against solid tumors. These approaches include strategies to conjugate T lymphocytes with cancer cells using chimeric antigen receptors (CARs) (, ) or bispecific antibodies recognizing cell-surface tumor-associated antigens (). Despite the fact that these two strategies promote the formation of functional ISs in terms of signals leading to LRO secretory polarized traffic and tumor cell death, the spatiotemporal architecture of the IS formed under these “artificial” redirecting strategies is different from that found in canonical, TCR-evoked synapses (, ). Canonical IS-tuned CAR signaling enhances the anti-tumor activity of CAR T cells and T-cell engaging bispecific antibodies () (), and recent evidence shows that IS quality measurements correlate with patient clinical outcomes (). Thus, the IS studies evoked during these approaches will indeed provide future experimental strategies to tune these “artificial” IS responses to improve T-cell effector anti-tumor responses ().
Among the most common complications in CAR-T therapy are the failure to produce autologous CAR-T cells, the loss of target antigen, the barriers imposed by the tumor microenvironment, and the lack of efficacy and persistence (exhaustion) of CAR-T cells, which may eventually lead to tumor cell evasion by affecting the therapeutic CAR-T effect (). In this context, we have received an interesting contribution from the NEXT Generation CART MAD Consortium (NEXT CART) (Martín-Antonio et al.), which is based on various basic and translational research groups and hospitals in Madrid (Spain) that have joined forces to share and synergize their basic expertise in IS, immunotherapy, gene therapy and their clinical expertise in pediatric and adult oncology. The aim of NEXT CART is to develop new cell engineering approaches and treatments for adult and pediatric neoplasms to be evaluated in multicenter clinical trials. The Consortium claims that “we will provide our perspective on how these strategies will evolve in the coming years to solve the main current limitations of these therapies”. Opportunities for advancement identified by the authors include developing allogeneic products, optimizing CAR signaling domains, combining cellular immunotherapies, multi-targeting strategies, and improving tumor-infiltrating lymphocyte (TIL)/TCR therapy.
Last but not least, with respect to IS-induced cell asymmetry, Gómez-Morón et al. submitted a relevant contribution showing how translation inhibition affects the asymmetric reorganization that occurs during CTL activation. The authors demonstrate that cytosolic protein translation is required to increase glucose metabolism and degranulation capacity upon TCR activation and thus regulate the full effector function of human CTLs. Interestingly, they observe that inhibition of translation shortly before TCR activation prevents proper reorganization of the tubulin cytoskeleton and asymmetric distribution of mitochondria. mTOR pathways are defectively activated in these cells and glucose metabolism through glycolysis and oxidative phosphorylation (OXPHOS) is affected. In this context, the movement of lytic granules (a type of LRO characteristic of CTLs) at the cell contact area with stimulating surfaces and the degranulation of CTLs are inhibited. Thus, the authors have linked the activity of 80S ribosomes and mitochondria to the ability of human CTLs to exert their effector functions in vitro.
Overall, our greatest reward has been to receive such relevant contributions, even after the deadline of the submission deadline, and to observe that the number of manuscript downloads and views is continuously increasing. We believe that thanks to the contributions included in this Research Topic, we have fulfilled our objective of editing a collection of articles that stimulates and facilitates a scientific forum for immunologists but also for clinicians, bridging the cross-disciplinary gap, increasing awareness, and maximizing the discussion and dissemination of ideas and methodologies in this emerging field.
Statements
Author contributions
MI: Writing – original draft, Writing – review & editing. JR: Writing – original draft, Writing – review & editing. CB: Writing – original draft, Writing – review & editing. PR: Writing – original draft, Writing – review & editing.
Acknowledgments
We would like to thank the Associate Editors and Editor Reviewers for their thoughtful comments and efforts to improve the manuscripts included in this Research Topic. Thanks to the Frontiers Editorial team for their collaborative support and for superb editing.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AlonsoRMazzeoCRodriguezMCMarshMFraile-RamosACalvoVet al. Diacylglycerol kinase alpha regulates the formation and polarisation of mature multivesicular bodies involved in the secretion of Fas ligand-containing exosomes in T lymphocytes. Cell Death differentiation. (2011) 18:1161–73. doi: 10.1038/cdd.2010.184
2
CalvoVIzquierdoM. Inducible polarized secretion of exosomes in T and B lymphocytes. Int J Mol Sci. (2020) 21:2631. doi: 10.3390/ijms21072631
3
CassioliCBaldariCT. The expanding arsenal of cytotoxic T cells. Front Immunol. (2022) 13:883010. doi: 10.3389/fimmu.2022.883010
4
AlonsoRRodriguezMCPindadoJMerinoEMeridaIIzquierdoM. Diacylglycerol kinase alpha regulates the secretion of lethal exosomes bearing Fas ligand during activation-induced cell death of T lymphocytes. J Biol Chem. (2005) 280:28439–50. doi: 10.1074/jbc.M501112200
5
YuseffMIPierobonPReversatALennon-DumenilAM. How B cells capture, process and present antigens: a crucial role for cell polarity. Nat Rev Immunol. (2013) 13:475–86. doi: 10.1038/nri3469
6
DustinMLChoudhuriK. Signaling and polarized communication across the T cell immunological synapse. Annu Rev Cell Dev Biol. (2016) 32:303–25. doi: 10.1146/annurev-cellbio-100814-125330
7
CalvoVIzquierdoM. Role of actin cytoskeleton reorganization in polarized secretory traffic at the immunological synapse. Front Cell Dev Biol. (2021) 9:629097. doi: 10.3389/fcell.2021.629097
8
McKenzieBKhazenRValituttiS. Greek fire, poison arrows, and scorpion bombs: how tumor cells defend against the siege weapons of cytotoxic T lymphocytes. Front Immunol. (2022) 13:894306. doi: 10.3389/fimmu.2022.894306
9
Ibanez-VegaJDel Valle BatallaFSaezJJSozaAYuseffMI. Proteasome dependent actin remodeling facilitates antigen extraction at the immune synapse of B cells. Front Immunol. (2019) 10:225. doi: 10.3389/fimmu.2019.00225
10
OckfenEFilaliLPereira FernandesDHoffmannCThomasC. Actin cytoskeleton remodeling at the cancer cell side of the immunological synapse: good, bad, or both? Front Immunol. (2023) 14:1276602. doi: 10.3389/fimmu.2023.1276602
11
McKenzieBValituttiS. Resisting T cell attack: tumor-cell-intrinsic defense and reparation mechanisms. Trends cancer. (2023) 9:198–211. doi: 10.1016/j.trecan.2022.12.003
12
Roda-NavarroPÁlvarez-VallinaL. Understanding the spatial topology of artificial immunological synapses assembled in T cell-redirecting strategies: A major issue in cancer immunotherapy. Front Cell Dev Biol. (2020) 7. doi: 10.3389/fcell.2019.00370
13
DagherOKPoseyAD. Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol. (2023) 24:1994–2007. doi: 10.1038/s41590-023-01659-y
14
BakerDJAranyZBaurJAEpsteinJAJuneCH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. (2023) 619:707–15. doi: 10.1038/s41586-023-06243-w
15
BlancoBCompteMLykkemarkSSanzLAlvarez-VallinaL. T cell-redirecting strategies to 'STAb' Tumors: beyond CARs and bispecific antibodies. Trends Immunol. (2019) 40:243–57. doi: 10.1016/j.it.2019.01.008
16
DavenportAJCrossRSWatsonKALiaoYShiWPrinceHMet al. Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc Natl Acad Sci U S A. (2018) 115:E2068–E76. doi: 10.1073/pnas.1716266115
17
ChockleyPJIbanez-VegaJKrenciuteGTalbotLJGottschalkS. Synapse-tuned CARs enhance immune cell anti-tumor activity. Nat Biotechnol. (2023) 41:1434–45. doi: 10.1038/s41587-022-01650-2
18
NaghizadehATsaoW-cHyun ChoJXuHMohamedMLiDet al. In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes. PloS Comput Biol. (2022) 18:e1009883. doi: 10.1371/journal.pcbi.1009883
Summary
Keywords
immune synapse, T lymphocytes, chimeric antigen receptor (CAR), actin cytoskeleton, T cell-redirecting strategies, secretory traffic
Citation
Izquierdo M, Ruiz-Navarro J, Baldari CT and Roda-Navarro P (2024) Editorial: Structure and function of the immunological and redirecting artificial synapses and their clinical implications. Front. Immunol. 15:1497118. doi: 10.3389/fimmu.2024.1497118
Received
16 September 2024
Accepted
20 September 2024
Published
03 October 2024
Volume
15 - 2024
Edited and reviewed by
Mariolina Salio, Immunocore, United Kingdom
Updates
Copyright
© 2024 Izquierdo, Ruiz-Navarro, Baldari and Roda-Navarro.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Manuel Izquierdo, mizquierdo@iib.uam.es; Cosima T. Baldari, cosima.baldari@unisi.it; Pedro Roda-Navarro, proda@med.ucm.es
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.